Experimental drug KST-401 is a biologically functional liquid crystal developed using a bioinformatic LCP™ drug discovery platform central to IC-MedTech's cell treatment rationale. Tolaquin, together with several related compounds in-licensed to the company in 2007, has applications in oncology and microbiology for the treatment of cancer and other diseases.
LCP™ and Liquid Crystal Pharmaceuticals™ are trademarks of IC-MedTech which designate products of therapeutic value within the company's family of biologically functional liquid crystals and liquid crystal applications.
IC-MedTech is headquartered in San Diego, CA and has strategic alliances, collaborations and sponsored research agreements with universities and pharma's in the US, Canada and Europe. |
